Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
The primary objective of this study is to evaluate the dose response, efficacy, and safety of
 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a
 fixed dose of fluticasone propionate (100 mcg) delivered as Fluticasone/Salmeterol Spiromax®
 Inhalation Powder (FS Spiromax) when administered as a single dose in subjects 12 years of
 age and older with persistent asthma.
This was a multicenter, randomized, double-blind and open-label active-controlled,
 single-dose, 6 period crossover, dose-ranging study conducted in male and female subjects
 ages 12 years and older with persistent asthma.

 Fluticasone propionate multidose dry powder inhaler (Fp MDPI) 50 mcg was provided (to replace
 the subject's current inhaled corticosteroid (ICS)) throughout the 14 day run-in period and
 each of the washout periods between treatments. Subjects were instructed to administer 2
 inhalations of Fp MDPI 50 mcg (100 mcg total dose) twice daily during the run-in and washout
 periods. All other medications for the treatment of asthma were discontinued at or prior to
 the screening visit.

 A short-acting β2-adrenergic agonist (SABA), salbuterol HFA, MDI, was provided (to replace
 the subject's current rescue medication) for symptomatic relief of asthma symptoms in each
 the run-in, treatment, and washout periods.

 Treatment period lasted 5 weeks with a 5 to 7 day washout between each of the six single dose
 treatments:

 -  fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) given
 in doses of 6.25, 12.5, 25, or 50 mcg of salmeterol xinafoate in blinded fashion.

 -  fluticasone propionate multidose dry powder inhaler (Fp MDPI) 100 mcg in blinded fashion

 -  ADVAIR DISKUS, 100/50 mcg in open-label fashion
Inclusion Criteria:

 -  Written informed consent/assent

 -  General good health

 -  Diagnosis of asthma as defined by the National Institutes of Health (NIH)

 -  A best FEV1 of 40%-85% of the predicted normal value during the screening visit (SV)

 -  Subjects need to demonstrate a ≥ 15% reversibility of FEV1 within 30 minutes following
 4 inhalations of albuterol inhalation aerosol (if required, spacers are permitted for
 reversibility testing) at the SV.

 -  Other inclusion criteria apply

 Exclusion Criteria:

 -  History of life-threatening asthma that is defined for this protocol as an asthma
 episode that required intubation.

 -  Culture-documented or suspected bacterial or viral infection of the upper or lower
 respiratory tract, sinus, or middle ear that is not resolved within 2 weeks prior to
 the SV.

 -  Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A
 subject must not have had any hospitalization for asthma within 6 months prior to the
 SV.

 -  Taking long-acting β-agonists within 2 weeks of the SV

 -  Other exclusion criteria apply.